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Abstract 
Cardiac neuroimaging with 123I-metaiodobenzyl guanidine (MIBG) has been officially used in clinical practice 
in Japan since 1992. The nuclear cardiology guidelines of the Japanese Circulation Society revised in 2010 
recommend cardiac 123I-MIBG imaging for the management of heart failure (HF) patients, particularly for the 
assessment of HF severity and prognosis of HF patients. Consensus in North American and European 
countries regarding incorporation into clinical practice, however, has not been established yet. This article 
summarizes 22 years of clinical applications in Japan of 123I-MIBG imaging in the field of cardiology, which 
are reflected in cardiology guidelines, including recent methodological advances. A standardized cardiac 123I-
MIBG parameter, heart-to-mediastinum ratio (HMR), is the basis for clinical decision-making and enables 
common use of parameters beyond differences in institutions and studies. A number of clinical studies 
unanimously demonstrated its potent independent roles for prognosis evaluation and risk stratification 
irrespective of HF etiologies. An HMR of less than 1.6 -1.8 and an accelerated washout rate are recognized as 
high-risk indicators of pump-failure death, sudden cardiac death and fatal arrhythmias, and have independent 
and incremental prognostic values together with known clinical variables such as left ventricular ejection 
fraction and brain-type natriuretic peptide. Another possible use of this imaging technique has been strongly 
suggested for selecting therapeutic strategy, such as pharmacological and non-pharmacological treatments, 
using an implantable cardioverter defibrillator and/or cardiac resynchronization device; however, this 
possibility remains to be investigated. Recent multiple-cohort database analyses definitively demonstrated that 
patients at a low risk for lethal events who are defined by 123I-MIBG HMR >2.0 have a good long-term 
prognosis. Future investigations of cardiac 123I-MIBG imaging will contribute to better risk stratification of 
low and high-risk populations, to the establishment of cost-effective use of this imaging technique for the 
management of HF patients, and to world-wide acceptance of this imaging technique in clinical cardiology 
practice 　 
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Multicenter studies using 123I-metaiodobenzylguanidine 
(MIBG) in North America, Europe and Japan recently 
demonstrated the prognostic efficacies of this 
neuroimaging technique (1-3). Japan has 22 years of 
experience in 123I-MIBG imaging in clinical cardiology 
practice. A number of single-center studies have clarified 
the clinical implications of cardiac 123I-MIBG imaging, 
which can depict noradrenaline uptake and release 
processes. In 1980, 131I-MIBG imaging first started as 
adrenal medullary imaging. In 1987, Daiichi 
Radioisotope Laboratory (Fujifilm RI Pharma, Co. Ltd, 
Tokyo, Japan, at present) performed a clinical trial of 
123I-MIBG (MyoMIBGTM) for imaging of the heart, after 
which the Japanese Ministry of Welfare (Ministry of 
Health, Labour and Welfare at present) approved the 
clinical use of 123I-MIBG in cardiology practice in 1992. 
Thereafter, Japan had a robust clinical experience dealing 
with heart diseases during these two decades, including 
ischemic heart disease, arrhythmia, idiopathic dilated 
cardiomyopathy, hypertrophic cardiomyopathy and 
cardiomyopathies secondary to diabetes, renal failure and 
other metabolic disorders. A majority of cardiac MIBG 
imaging, however, has been performed most effectively 
for chronic heart failure (HF), and their achievements are 
summarized in the Japanese Circulation Society’s 
Guidelines: Guidelines for Clinical Use of Cardiac 
Nuclear Medicine (2010, English digest version 2012) 
(4).  
 In the 1990’s, 123I-MIBG imaging was applied to 
neurological indications such as Lewy-body diseases, 
which includes Parkinson disease, dementia with Lewy 
bodies and pure autonomic failure. Since then, MIBG 
imaging has contributed to effective identification of 
Lewy body involvement in the heart. Neurological 
experiences in the past decade and incorporation into the 
Japanese neurological guidelines have facilitated the 
clinical use of 123I-MIBG in this field (5), resulting in 
official approval by Japanese social health insurance. In 
1993, 131I-MIBG was approved in the field of oncology, 
and the clinical indications of 123I-MIBG included 
neuroblastoma and pheochromocytoma at present.  
 This review surveys a history of cardiac 123I-
MIBG imaging, recent advances in standardization of 
this imaging technique, and major achievements in 
cardiology. Lastly we discuss the possible efficacies and 
future directions for clinical decision-making in the 
management of HF.   
Number of MIBG studies in Japan
 The utility of 123I-MIBG since 2000 is 
summarized in the Report of the Nationwide Survey 
“The Present State of Nuclear Medicine Practice by 
Japan Radioisotope Association”. The number of 
myocardial perfusion imaging with single-photon 
emission computed tomography (SPECT) was about 
300,000 studies per year, while approximately 40,000 
studies were performed for 123I-MIBG. According to data 
from another report (Reports on Survey of the Adverse 
Reaction to Radiopharmaceuticals (2002-2012), http://
www.jsnm.org/system/files/k-51-1-01.pdf ) the annual 
number of 123I-MIBG studies was 33,000 for heart and 
4,000 for oncology, and the increase in 123I-MIBG studies 
was +12% from 2011 to 2012 (Figure 1). The use of 123I-
MIBG in HF is estimated to be approximately 10,000 
studies per year. At a multi-modality era, the use of 
myocardial perfusion SPECT has slightly decreased in 
recent years in Japan, but it is noteworthy that the use of 
MIBG imaging has been gradually increasing.  
  
Clinical use of 123I-MIBG leading to Japanese 
nuclear cardiology guidelines
 In the field of cardiology, the utility of MIBG was 
applied to ischemic heart disease, and high sensitivities 
for the detection of myocardial ischemia were reported. 
After early success of coronary revascularization in 
patients with acute coronary syndrome, salvaged 
myocardium could be visualized as denervated but viable 
tissue in an area at risk by MIBG SPECT (6,7). Cardiac 
123I-MIBG imaging was also used for the identification of 
repeated ischemia due to coronary artery spasm (8,9). 
The applications of cardiac 123I-MIBG imaging are 
possibly useful for the detection of undetermined, 
unstable or recurrent ischemia without a stress test. The 
low image quality and nonspecific abnormality of the 
inferior wall (a low specificity) on cardiac 123I-MIBG 
SPECT imaging, however, limits the application of this 
imaging technique for coronary artery disease. Stress 
myocardial perfusion imaging and myocardial fatty acid 
metabolism imaging with 123I-beta methyl iodophenyl 
pentadecanoic acid are more widely preferred for 
detecting myocardial ischemia or ischemia-related 
myocardial injury in Japan, based on the Japanese 
Circulation Society guidelines of nuclear imaging.  
 Cardiac 123I-MIBG imaging plays a unique and 
pivotal position in clinical heart failure practice. While 
ischemic HF is the most common etiology of HF in 
western countries, in Japan non-ischemic HF is more 
common (2). Non-ischemic dilated cardiomyopathy has 
been one of the important applications of cardiac 123I-
MIBG imaging since the 1990s in Japan, although it is 
also important in North America and Europe (10-12). 
Regardless of HF etiology, reduced cardiac 123I-MIBG 
activity quantified as heart-to-mediastinum ratio (HMR) 
has been shown consistently to indicate poor cardiac 
survival. As discussed later, cardiac 123I-MIBG imaging 
can evaluate pharmacological effects of inhibitors of the 
beta-adrenoceptor function and renin-angiotensin-
aldosterone system, showing good efficacies of these 
drugs parallel to the improvement in HMR and 123I-
MIBG washout rate (WR) in responders. Hypertrophied 
myocardium has reduced 123I-MIBG activity relative to 
perfusion tracer uptake together with increased 123I-
MIBG clearance in patients with hypertrophic 
cardiomyopathy (13). A diabetic heart is also likely to 
have impaired 123I-MIBG activity (low HMR and 123I-
MIBG defect) in association with disease progression 
(14). Table 1 summarizes major investigations that 
prospectively followed up chronic HF patients for more 
than 2 years with an endpoint of cardiac death (15-25). 
 Table 2 shows pooled or multicenter analysis in 
Japan, North America and Europe. Based on the clinical 
applications of 123I-MIBG and literature from Europe, 
North America and Japan, the Japanese Circulation 
Society published the Guidelines for Clinical Use of 
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Cardiac Nuclear Medicine in 2005 and revised them in 
2010 by reviewing recent achievements (Table 3) (4).  
Recommended protocols in Japan 
Acquisition protocol 
 An 123I-MIBG scan is performed 15-30 minutes 
(early) and 3-4 hours (late) after the tracer injection. A 
commonly used dose of 123I-MIBG in Japan is 111 MBq, 
less than the recommended dose (111-370 MBq) in the 
USA and Europe (26). A planar image is obtained from 
an anterior view for 3 to 10 minutes using an energy 
window centered on 159 keV and a window width of 
20% or 15%. When possible, tomographic data are 
subsequently acquired for the differential diagnosis and 
detection of localization of 123I-MIBG defects in 
coronary artery disease and neurodegenerative disorder 
such as Lewy-body related diseases (5). Cardiac 123I-
MIBG activity is affected by the imaging condition, 
particularly a collimator type; HMR obtained by a 
medium-energy (ME) collimator is greater than that by a 
low-energy (LE) one.  
Parameters from 123I-MIBG study 
 HMR is the most widely used 123I-MIBG 
parameter for the measurement of whole myocardial 
activity. A cardiac region of interest (ROI) is set 
manually over the heart without overlapping lung and 
liver activities, and with a rectangular mediastinal ROI as 
a background (26). The reproducibility of HMR is good 
as long as it is used in the same institution (27), although 
variability is observed depending on selections of ROI 
size and location and operator’s experience. Recently, 
software (smartMIBG, Fujifilm RI Pharma, Co. Ltd, 
Japan) has become available for semiautomatic ROI 
settings and calculations of HMR and WR (28). The 
software algorithm uses a circular heart ROI and a 
mediastinal ROI with a 10% width of the body and a 
30% height of the mediastinum. HMR is calculated as an 
average heart count per pixel divided by an average 
mediastinal count per pixel. Washout rate (WR) is also 




where Hearly and Hlate are average heart counts and Mearly 
and Mlate are average mediastinal counts at early and late 
scans, respectively. The coefficient k is a time-decay 
correction factor of [0.5^(t/13)]-1 for time t (h), and if the 
interval between the scans is 3 hours, k is 1.17. Ideally 
the tracer kinetic (WR) can be estimated precisely by 
using both background and physical-decay corrections. 
These corrections, however, are not necessarily 
performed routinely, and WR in the previous literature 
should be carefully interpreted in this context. Although 
no background subtraction may be used for less 
variability (27), our recommendation is to use 
background subtraction for consistency among various 
studies other than HF. 
Regional vs. global, Planar vs. SEPCT 
 SPECT imaging can assess regional 123I-MIBG 
defects, which indicate viable but denervated, or injured 
myocardial tissue. The Japanese Society of Nuclear 
Medicine (JSNM) working group database is the first 
123I-MIBG SPECT database created for 180-degree and 
360-degree rotations in each gender (Figure 2) (29). 
However, there are several limitations in SPECT 
imaging. First, even in near-normal subjects, an inferior 
wall activity is often decreased, probably because of 
physiological change brought on by aging. Second, when 
cardiac 123I-MIBG activity is globally and markedly 
reduced as often seen in advanced heart failure, 
reconstruction of SPECT image and regional assessment 
using a scoring system are difficult to achieve. Third, in a 
highly dilated heart, non-specific inferior wall defects are 
observed probably because of attenuation artifacts. 
Finally, inferior wall defects are also observed in diabetic 
hearts. Thus, while regional assessment of 123I-MIBG 
distribution with a high-image quality is useful for the 
detection of localized denervation, it seems to be 
supplementary to the global assessment of 123I-MIBG 
activity in HF. 
Normal values and standardization
Normal values 
 Standardization of HMR and WR is necessary for 
setting a normal value and optimal threshold for risk-
stratification. In a survey using 12 sources from literature 
from Japan from1994 to 2007, the means of early and 
late HMRs in the normal (control) groups ranged from 
1.88 to 2.87 and from 1.84-2.49, respectively (references 
in supplementary file). In the normal JSNM databases, 
early and late HMRs are 2.39±0.21 and 2.49±0.25 for the 
LE collimator, and 2.76±0.31 and 3.01±0.35 for the ME 
collimator, respectively (29). Similarly, in 11 studies in 
Europe and the United States, late HMR ranged from 
1.77 to 2.50 (references in supplementary file). Figure 2 
shows mean normal HMR obtained with each collimator 
and standardized HMR from JSNM working group 
databases (n=62).  
Standardization of HMR for prognostic evaluation 
 There are large variations in HMR value 
depending on a scinticamera, collimator, administration 
dose and specific activity of 123I-MIBG, and imaging 
protocol. In particular, high-energy photons in 123I, 
particularly the 529 keV photon (1.4%), result in 
numerical differences between measurements from LE- 
and ME-collimated images. Therefore, a dichotomous 
manner of risk-assessment (low- versus high-risk) using 
a HMR threshold may be questionable (30). However, it 
is critical and possible to standardize 123I-MIBG 
parameters (HMR and WR) for the clinical application in 
the management of HF. Figure 3 shows one of the 
promising processes for appropriate utilization of 123I-
MIBG parameters, i. e. HMR, in the clinical decision-
making in chronic HF patients. We proposed a 
calibration-phantom method to cross calibrate HMRs 
among institutions (31,32). Because HMRs between two 
camera-acquisition conditions have an approximately 
linear relation, a conversion formula between two 
systems can be determined using the cross-calibration 
phantom designed for the planar imaging. Using this 
calibration method, the conversion coefficient from an 
institutional HMR to the mathematically calculated 
reference value was measured in 225 experiments in 84 
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hospitals. The measured HMR was successfully 
converted to standardized HMR among institutions. Our 
proposal was to use the standardized HMR comparable to 
that obtained with the ME-type collimator, which is most 
fitted for 123I-tracer currently available for heart and brain 
studies. The standardization of HMR significantly 
improved risk classification based on HMR either with 
LE or ME collimators (32). HMRs published in several 
works of literature also can be changed to specific 
conditions. Provided that the ADMIRE-HF study showed 
the HMR threshold was 1.6 using the LEHR collimator 
(1), the threshold can be converted to 2.0 for the 
institution in which the ME general-purpose collimator is 
used. Figure 4 demonstrates the results of data 
conversion and incorporation of standardized HMR into 
the mortality risk model (2,33). Thus, this method 
enables calibration of data obtained by any kind of HMR, 
either by ME or LE collimators, contributing to universal 
application and comparison of HMR in the decision-
making for selecting a therapeutic strategy.  
Incremental clinical benefits of cardiac 123I-MIBG 
imaging in the HF
A number of works of literature have demonstrated 
independent and incremental prognostic values of cardiac 
123I-MIBG imaging in chronic HF patients in 
combination with clinical information, such as a history 
of myocardial infarction, New York Heart Association 
(NYHA) functional class, left ventricular ejection 
fraction (LVEF), plasma brain natriuretic peptide (BNP) 
level and co-existing non-cardiac conditions as diabetes 
mellitus, impaired kidney function and anemia 
(2,10,15,19,20,25,34-36). The prognostic value is also 
shown irrespective of etiologies (ischemic or non-
ischemic) of HF and LVEF (Figure 5) (35). Cardiac 123I-
MIBG imaging can help cardiologists risk-stratify 
patients, select therapeutic strategy and predict long-term 
survival in chronic HF patients more precisely. Recent 
results from the multicenter studies (1-3) strengthened 
the previous findings demonstrating that cardiac 123I-
MIBG imaging can risk-stratify (low-risk versus high-
risk for lethal events) patients with HF and predict the 
probability of long-term survival with pharmacological 
or non-pharmacological treatments.  
Pharmacological treatment and cardiac 123I-
MIBG imaging 
Because of the definitive mortality improvement, 
beta-blockers and renin-angiotensin-aldosterone system 
inhibitors are widely accepted in patients with 
asymptomatic and symptomatic chronic HF. Risk 
reduction rates for cardiac mortality by these 
medications, however, are still limited, that is roughly 
20% to 30%. In real-world practice, some chronic HF 
patients do not necessarily meet entry criteria used in 
major drug-interventional HF studies or often have co-
existing or unexpected non-cardiac diseases affecting 
clinical outcomes. Some chronic HF patients cannot 
sufficiently benefit from these drug treatments as non-
responders or due to intolerance or adverse effects to 
these drugs, and physician’s preference sometimes results 
in under-use or under-dose of these drugs. It is, therefore, 
highly desirable to establish a method to appropriately 
identify patients who sufficiently respond and tolerate 
contemporary drug therapy beyond physician’s 
preference or experience. Although only a few studies 
have been conducted (11,37-46), cardiac 1123I-MIBG 
imaging can monitor effects of drug treatment using beta-
blocking agents, renin-angiotensin-aldosterone inhibitors 
or their combinations by correlating an increase in 
cardiac 123I-MIBG activity (HMR) and a decrease in 123I-
MIBG WR with the improvement in NYHA functional 
class, LVEF or exercise tolerance.  
Despite the data, It is more crucial to predict 
therapeutic efficacy and outcome improvement before 
the initiation of drug intervention. Patients with 
preserved cardiac HMR of 1.8 or more are shown to be 
tolerant to a metoprolol titration dose and the findings 
were more likely to be related to subsequent 
improvement in cardiac function during a 3-month 
interval together with a reduction in plasma 
noradrenaline concentration (39). In 167 chronic HF 
patients (45), treatment with ACE inhibitors and/or beta-
blockers significantly reduced cardiac death prevalence 
and a 5-year cardiac mortality rate compared to that 
without these drugs (15% vs 37% and 21% vs 42%, 
p<0.05, respectively), and a risk reduction rate at 5 years 
in patients with HMR of 1.53 or more was significantly 
greater than that in those with HMR of less than 1.53 
under the contemporary drug treatment (67% vs 32%, 
respectively; p<0.05). Thus, current optimal drug 
treatment can improve a survival rate, but the efficacy on 
clinical outcomes is likely to depend on cardiac 123I-
MIBG activity, strongly suggesting that cardiac 123I-
MIBG activity cannot only estimate drug effects but also 
predict cardiac risk improvement by appropriate drug 
treatment.  
Needs for a new risk-stratification method in 
device treatment
There are inherent limitations in contemporary 
drug treatment, that is, some patients are originally non-
responders or cease to respond to the contemporary drug 
therapy during a clinical course. Non-pharmacological 
device treatment has evolved to definitively improve 
symptoms, the quality life and outcomes for such patients 
with refractory HF. An implantable cardioverter 
defibrillator (ICD) can ablate lethal ventricular 
tachyarrhythmias and reduce sudden cardiac death (SCD) 
risk. Cardiac resynchronization therapy (CRT) using 
biventricular pacemakers can effectively reduce recurrent 
hospitalization and mortality risk in patients with 
prominent left bundle branch block and advanced systolic 
HF refractory to optimal drug treatment. CRT combined 
with ICD (CRTD) can reduce all-cause mortality, cardiac 
death and recurrence of symptomatic aggravation and 
hospitalization in patients with advanced HF in NYHA 
class 3-4 and severe intra-ventricular dyssynchrony (47). 
In addition to the secondary prevention of SCD or lethal 
arrhythmic events, the most accepted ICD indication for 
primary prevention of SCD is based on chronic HF 
presenting with prior myocardial infarction, NYHA class 
2-3 and LVEF of 35% or less.  
As introduced in major guidelines, continuous 
growth of the patient number and a robust amount of 
evidence relating to the efficacies of device therapy have 
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facilitated prophylactic use of ICD, CRT and CRTD in 
other developed countries as well as in Japan. It is 
known, however, that a large percentage of ICD devices 
are unlikely to deliver appropriate therapy during their 
lifetime, and nearly one third of patients ineligible for an 
ICD (LVEF > 35%) die of SCD. Likewise, clinical 
efficacies of CRT are limited in patients who have mild 
to moderate chronic HF (NYHA class 1-2), do not have a 
prolonged QRS duration of greater than 120 msec, or do 
not have reduced LVEF. Some patients cannot respond 
adequately to or might be ineligible (at a really low risk) 
for the device treatment even when patients meet 
currently available standard indication criteria. 
Conversely, even when the patients are outside the 
indication criteria, some patients might die of SCD 
(consequently at high risk) and are eligible for the 
treatment.  Besides device-related problems, 
the increasing need for medical resources, which are 
becoming limited, heightens the need to establish more 
appropriate identification - beyond that provided by 
conventional clinical markers - of patients who have 
chronic HF and are most likely or unlikely to benefit 
from device treatment in a cost-effective fashion (48-51).  
Cardiac 123I-MIBG imaging in device treatment
The Department of Japanese Government 
Social Insurance officially approved ICD use in 1996, 
CRT in 2004, then CRTD in 2006. Thereafter, several 
small but important studies (22,52-58) have shown that 
excess activation of cardiac sympathetic nerve function 
and impaired cardiac sympathetic innervation assessed 
by cardiac 123I-MIBG imaging are associated with 
arrhythmogenecity leading to lethal ventricular 
arrhythmias, ICD shock against lethal arrhythmic events 
and SCD independently of clinical, electrophysiological 
and LVEF (59). In addition to the assessment of BNP, 
LVEF and myocardial viability, cardiac 123I-MIBG 
activity is used for the prognosis assessment and 
selection of therapeutic strategy in our institutes (56,57). 
The incremental prognostic values of this imaging 
technique are also supported by larger studies (60,61) and 
by the positron emission tomography (PET) study using 
11C-meta-hydroxyephedrine (HED) (62). Cardiac 123I-
MIBG imaging has additive values to clinical 
information assessed by Seattle Heart Failure Model in 
high-risk candidates for ICD, CRT or CRTD (61); and 
arrhythmic death or appropriate ICD discharge for lethal 
ventricular arrhythmias correlates with amounts of 
denervated myocardium (62). In response to CRT, 
cardiac 123I-MIBG activity improves together with 
symptomatic and functional improvement, and baseline 
cardiac 123I-MIBG activity correlates with CRT effects 
(63-66). More recently, cardiac 123I-MIBG activity is 
shown to be closely associated with mechanical 
dyssynchrony assessed by a speckle-tracking strain 
technique and 123I-MIBG HMR of 1.6 is likely to be a 
cut-off value for predicting response to CRT and long-
term outcomes in combination with dyssynchrony in 
Japanese patients (67). Thus, cardiac 123I-MIBG imaging 
enables cardiologists to help identify patients who are 
most susceptible to lethal arrhythmias and event risks and 
who can actually benefit most from the device therapy by 
overcoming the limitations of current device therapy 
criteria, a majority of which consist of surrogate markers 
of lethal events such as symptoms (NYHA class), clinical 
backgrounds, LVEF and QRS prolongation (intra-
ventricular electrical dyssynchrony). 
Cardiac 123I-MIBG imaging in heart 
transplantation
Heart transplantation for patients with terminal 
HF improves survival rates at 1- and 5 years, up to nearly 
90% and 70%, respectively. Because of a limited number 
of heart donors, however, the precise indication, the order 
of priority and appropriate timing of operation are crucial 
clinical issues. Historically, due to delayed national 
consensus on this treatment and due to few donors, Japan 
has much less experience with heart transplantation per 
se compared to other counties and, therefore, has no 
significant clinical data using cardiac 123I-MIBG imaging 
on this treatment. Nevertheless, cardiac 123I-MIBG 
imaging possibly contributes to improvement in 
determination of the necessity of heart transplantation 
and expected survival interval than other standard 
parameters (3,12,68,69) in an era when advance device 
therapy combined with optimal drug treatment and 
cardiac 123I-MIBG imaging are available. Cardiac 123I-
MIBG imaging may be also useful for the assessment of 
re-innervation in transplanted hearts. Cardiac 
neuroimaging using 11C-HED or 123I-MIBG identifies 
ventricular sympathetic reinnervation (70-72), which 
slowly develops from the cardiac base several months 
after surgery and is observed in 40% of heart-
transplanted patients one year after the operation (73). 
Although clinical implications and mechanisms of the 
cardiac reinnervation process are not necessarily 
revealed, restoration of cardiac sympathetic innervation 
is likely to increase exercise capacity by improving 
blunted physiologic response of heart rate and contractile 
function to exercise in patients with heart transplantation 
(73). Assessment of the cardiac reinnervation process by 
cardiac 123I-MIBG imaging may be useful for the 
management of patients with heart transplantation in an 
outpatient care unit, by determining the appropriate 
exercise prescription, evaluating the exercise training 
effect and, hopefully, predicting improvement in long-
term survival.  
Identification of low-risk patients with HF 
 Cost-effective treatment is generally a risk-
based selection of therapeutic strategy. Precise 
identification of patients at low risk for lethal outcomes 
can contribute to appropriate use of medical resources by 
minimizing diagnostic examinations, selecting a low-cost 
but effective treatment appropriately and restraining from 
over-use of high-cost intervention in patients who are not 
so likely to benefit from a high-cost, invasive treatment. 
Previous investigations show that the cut-off value for 
differentiating high- from low-risk patients is likely from 
around 1.60 to 1.75 (1-3,15). Furthermore, the recent 
multicenter results from more than 600 to 1,300 chronic 
HF patients (1-3) definitively demonstrated the ability of 
cardiac 123I-MIBG imaging for the identification of low-
risk patients who can survive over several years 
!  5
!  6
independently of conventional prognostic markers 
(Figure 6). In the Japanese study (2,33), annual all-cause 
mortality was less than 2% in patients with HMR≥2.0, 
and a mortality rate at 5 years was nearly 8% in patients 
with HMR≥2.0 and 10% to 15% in patients with HMR 
between 1.7 and 2.0. Likewise, a mortality rate at 5 years 
was less than 3% in patients with HMR≥1.76 and nearly 
15% in patients with HMR between 1.33 and 1.75 in the 
European study (3). What is noted here is that HMR cut-
off values are different among the studies (1-3). As 
discussed above, this is because of the differences in 
patient backgrounds and, more importantly, because of 
technical differences in cardiac 123I-MIBG imaging (32). 
Nevertheless, cardiac 123I-MIBG activity quantified as 
HMR correlates consistently with a survival rate during a 
5-year period or more over a wide range of HMR from 
less than 1.1 to 2.1 or more (2). Thus, these findings and 
recent advances in standardization of cardiac 123I-MIBG 
imaging presented in this article can facilitate clinical use 
of the quantitative 123I-MIBG parameter (HMR) for 
defining a low-risk probability of lethal events over 5 
years (33), for the differentiating high- and low-risk 
patients and for anticipating a survival time in each 
chronic HF patient.  
Limitations and future direction of cardiac 123I-
MIBG imaging 
A growing body of evidence of cardiac 123I-
MIBG imaging demonstrates great potential in helping 
select patients who are most eligible for advanced 
contemporary treatment rather than for treatment through 
conventional methods. Further investigations, however, 
are needed to strengthen prior findings and reassurance 
for precise risk-stratification and decision-making on the 
selection of non-pharmacological device treatment, 
including the prediction of responsiveness to the 
treatment. The increasing number of chronic HF patients 
will limit medical costs and application of device/heart 
transplantation treatment in patients at a lower risk or 
who are less likely to sufficiently benefit from the 
treatment in the future. More experience in cardiac 123I-
MIBG imaging is needed to improve negative and 
positive predictive values for better differentiation of 
low-risk and high-risk patients, which will contribute to 
effective use of medical resources. Unlike in Japan, the 
utility of this imaging technique is still less obvious in 
other countries for recommendation into international 
guidelines, yet there are still insufficient data relating to 
cost-effectiveness and limited availability in cardiology 
practice. Future large-scale prospective multicenter 
studies would establish a practical and cost-effective 
utilization of cardiac 123I-MIBG imaging in combination 
with clinical information in chronic HF patients to help 
clinicians optimize patient care (Table 4).   
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Normal values of HMR (A), washout rate (B) and polar maps (C) based on JSNM working group databases. 





Standardization of cardiac 123I-MIBG activity quantified as heart-to-mediastinum ratio (HMR) by converting 
data obtained using a low-medium-energy (LME) collimator to those using a low-energy high-resolution 
(LEHR) collimator. A: a 32-year old male with 22% of left ventricular ejection fraction (LVEF) and NYHA 
class III. The HMR was converted from 1.36 in a LME collimator to 1.23 in a LEHR collimator and a 5-year 
mortality rate was re-estimated to be more than 50% (10%/year). B: an 86-year old woman with LVEF 51% of 
and NYHA class II. Her HMR was converted from 2.33 to 1.88 and a 5-year mortality rate was re-calculated 





Standardization process of cardiac 123I-MIBG data for the calculation of heart (H)-to-mediastinum (M) ratio 





Cumulative mortality curves comparing patients with idiopathic dilated cardiomyopathy (A) or coronary 






Low risk of mortality in subjects with HMR >2.0. All-cause mortality curves for 10 years in Japanese pooled 
databases (n=1322) (2), indicating a low probability of lethal events independently of left ventricular ejection 
fraction (LVEF) when 123I-MIBG heart-to-mediastinum ratio (HMR) is more than 2.0 (A). Cardiac mortality 
curves at 5 years estimated by the logistic model of 123I-MIBG HMR (n=933) (33), indicating a low 
probability of lethal events independently of age-difference when 123I-MIBG HMR is more than 2.0 (B).  
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ACD, all-cause death; CD, cardiac death; SCD, sudden cardiac death; HF, heart failure; FABP, Heart-type 
fatty acid binding protein; DCM, dilated cardiomyopathy; HFPEF, heart failure with preserved ejection 
fraction  
Table 1. 123I-MIBG prognostic study in Japan with an endpoint of death
Author 
[Ref]
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2011 86 (57) DCM 110 
months
1.45 50% HMR, 
LVEF


















CD CD 89 19.0%
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ACD, all-cause death; CD, cardiac death; SCD, sudden cardiac death; HF, heart failure; FABP, Heart-type 
fatty acid binding protein; DCM, dilated cardiomyopathy; HFPEF, heart failure with preserved ejection 
fraction 
Table 2. Pooled or multicenter analysis in Japan, North America and Europe
Author 
[Ref]




























































































Table 3. Recommendations for 123I-MIBG sympathetic imaging in the Japanese Circulation Society’s 
Guidelines: Japanese Circulation Society Joint Working Group - Guidelines for Clinical Use of 
Cardiac Nuclear Medicine (4). 
       
Class I, Conditions for which there is evidence and/or general agreement that a given test is useful and 
effective; Class II, Conditions for which there is conflicting evidence and/or a divergence of opinion about the 
usefulness of a test; IIa, Weight of evidence/opinion is in favor of usefulness; IIb, Weight of evidence/opinion 
is less established based on evidence or opinion; Level B, Verified by ≥2 multicenter randomized intervention 
trials on <400 patients, well-designed comparative studies, or large-scale cohort studies; Level C, Consensus 
opinion of specialists 
Table 4. Current tentative clinical use of cardiac 123I-MIBG imaging in heart failure (HF) 




Assessment of severity and prognosis of heart failure I B
Assessment of treatment effects of heart failure IIa C
Arrhythmogenic disease IIb C
Purpose Utility
Severity Evaluation of severity of HF
Risk Risk-stratification of HF: high-risk and low-risk assessment
Risk assessment of ventricular tachyarrhythmias and lethal arrhythmic events
Therapy Evaluation of therapeutic effects of pharmacological and non-pharmacological 
treatment
Prediction of therapeutic response
Prognosis Prediction of long-term survival
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Supplement for normal values of 123I-MIBG studies
Cardiac 123I-MIBG Imaging for Clinical Decision 
Making: 22-year Experience in Japan 
Kenichi Nakajima, Tomoaki Nakata 
J Nucl Med 2015 56:11S-19S 
Heart-to-mediastinum ratios in the control groups in the 
literature of Japan (1-12) and in Europe and USA (13-23) 
are listed. 
1. Nakajima K, Taki J, Tonami N, Hisada K. 
Decreased 123I-MIBG uptake and increased clearance in 
various cardiac diseases. Nucl Med Commun. 
1994;15(5):317-323. 
2. Takeishi Y, Sukekawa H, Sakurai T, et al. 
Noninvas ive iden t i f i ca t ion o f an thracyc l ine 
cardiotoxicity: comparison of 123I-MIBG and 123I-
BMIPP imaging. Ann Nucl Med. 1994;8(3):177-182. 
3. Suwa M, Otake Y, Moriguchi A, et al. 
Iodine-123 metaiodobenzylguanidine myocardial 
scintigraphy for prediction of response to beta-blocker 
therapy in patients with dilated cardiomyopathy. Am 
Heart J. 1997;133(3):353-358. 
4. Nakata T, Miyamoto K, Doi A, et al. Cardiac 
death prediction and impaired cardiac sympathetic 
innervation assessed by MIBG in patients with failing 
and nonfailing hearts. J Nucl Cardiol. 1998;5(6):579-590. 
5. Orimo S, Ozawa E, Nakade S, Sugimoto T, 
Mizusawa H. (123)I-metaiodobenzylguanidine 
myocardial scintigraphy in Parkinson's disease. J Neurol 
Neurosurg Psychiatry. 1999;67(2):189-194. 
6. Yano T, Yamabe H, Yokoyama M. Washout 
rate of 123I-metaiodobenzylguanidine increased by 
posture change or exercise in normal volunteers. Ann 
Nucl Med. 1999;13(2):89-93. 
7. Fukuoka S, Nakagawa S, Fukunaga T, Yamada 
H. Effect of long-term atrial-demand ventricular pacing 
on cardiac sympathetic activity. Nucl Med Commun. 
2000;21(3):291-297. 
8. Mu X, Hasegawa S, Yoshioka J, et al. Clinical 
v a l u e o f l u n g u p t a k e o f i o d i n e - 1 2 3 
metaiodobenzylguanidine (MIBG), a myocardial 
sympathetic nerve imaging agent, in patients with 
chronic heart failure. Ann Nucl Med. 2001;15(5):
411-416. 
9. Arimoto T, Takeishi Y, Fukui A, et al. 
Dynamic 123I-MIBG SPECT reflects sympathetic 
nervous integrity and predicts clinical outcome in 
patients with chronic heart failure. Ann Nucl Med. 
2004;18(2):145-150. 
10. Nagayama H, Hamamoto M, Ueda M, 
Nagashima J, Katayama Y. Reliability of MIBG 
myocardial scintigraphy in the diagnosis of Parkinson's 
disease. J Neurol Neurosurg Psychiatry. 2005;76(2):
249-251. 
11. Sakata K, Iida K, Kudo M, Yoshida H, Doi O. 
Prognostic value of I-123 metaiodobenzylguanidine 
imaging in vasospastic angina without significant 
coronary stenosis. Circ J. 2005;69(2):171-176. 
12. Kasama S, Toyama T, Hatori T, et al. 
Evaluation of cardiac sympathetic nerve activity and left 
ventricular remodelling in patients with dilated 
cardiomyopathy on the treatment containing carvedilol. 
Eur Heart J. 2007;28(8):989-995. 
13. Claus D, Feistel H, Brunholzl C, Platsch G, 
Neundorfer B, Wolf F. Investigation of parasympathetic 
and sympathetic cardiac innervation in diabetic 
neuropathy: heart rate variation versus meta-iodo-
benzylguanidine measured by single photon emission 
computed tomography. Clin Auton Res. 1994;4(3):
117-123. 
14. Merlet P, Benvenuti C, Moyse D, et al. 
Prognostic value of MIBG imaging in idiopathic dilated 
cardiomyopathy. J Nucl Med. 1999;40(6):917-923. 
15. Cohen-Solal A, Esanu Y, Logeart D, et al. 
Cardiac metaiodobenzylguanidine uptake in patients with 
moderate chronic heart failure: relationship with peak 
oxygen uptake and prognosis. J Am Coll Cardiol. 
1999;33(3):759-766. 
16. Delahaye N, Dinanian S, Slama MS, et al. 
Cardiac sympathetic denervation in familial amyloid 
p o l y n e u r o p a t h y a s s e s s e d b y i o d i n e - 1 2 3 
metaiodobenzylguanidine scintigraphy and heart rate 
variability. Eur J Nucl Med. 1999;26(4):416-424. 
17. Druschky A, Hilz MJ, Platsch G, et al. 
Differentiation of Parkinson's disease and multiple 
system atrophy in early disease stages by means of I-123-
MIBG-SPECT. J Neurol Sci. 2000;175(1):3-12. 
18. Agostini D, Belin A, Amar MH, et al. 
Improvement of cardiac neuronal function after 
carvedilol treatment in dilated cardiomyopathy: a 123I-
MIBG scintigraphic study. J Nucl Med. 2000;41(5):
845-851. 
19. Marketou ME, Simantirakis EN, Prassopoulos 
VK, et al. Assessment of myocardial adrenergic 
innervation in patients with sick sinus syndrome: effect 
of asynchronous ventricular activation from ventricular 
apical stimulation. Heart. 2002;88(3):255-259. 
20. Parthenakis FI, Prassopoulos VK, Koukouraki 
SI, et al. Segmental pattern of myocardial sympathetic 
denervation in idiopathic dilated cardiomyopathy: 
relationship to regional wall motion and myocardial 
perfusion abnormalities. J Nucl Cardiol. 2002;9(1):15-22. 
21. Somsen GA, Verberne HJ, Fleury E, Righetti 
A. Normal values and within-subject variability of 
cardiac I-123 MIBG scintigraphy in healthy individuals: 
implications for clinical studies. J Nucl Cardiol. 
2004;11(2):126-133. 
22. Cha YM, Oh J, Miyazaki C, et al. Cardiac 
resynchronization therapy upregulates cardiac autonomic 
control. J Cardiovasc Electrophysiol. 2008;19(10):
1045-1052. 
23. Chen J, Folks RD, Verdes L, Manatunga DN, 
Jacobson AF, Garcia EV. Quantitative I-123 mIBG 
SPECT in differentiating abnormal and normal mIBG 
myocardial uptake. J Nucl Cardiol. 2012;19(1):92-99.
!  19
